CB-1158 is primarily used in the field of cancer research and therapy. It functions as an inhibitor of arginase, an enzyme that plays a role in the suppression of the immune system within the tumor microenvironment. By inhibiting arginase, CB-1158 helps to enhance the immune system's ability to attack cancer cells. This makes it a promising candidate for immunotherapy, particularly in combination with other treatments like checkpoint inhibitors. Its application is being explored in various preclinical and clinical studies to assess its efficacy in treating different types of cancers, including solid tumors and hematologic malignancies. The goal is to improve patient outcomes by boosting the body's natural defenses against cancer.